These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33682008)

  • 1. Invasive, aggressive mastoid bone eumycetoma: a treatment challenge.
    Yosif AA; Bakhiet SM; Abdalla TH; Mhmoud NA; Siddig EE; Fahal AH
    Trans R Soc Trop Med Hyg; 2021 Apr; 115(4):431-435. PubMed ID: 33682008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Madurella mycetomatis infection of the buttock in an Eritrean refugee in Switzerland: a case report.
    Mekoguem C; Triboulet C; Gouveia A
    J Med Case Rep; 2019 Feb; 13(1):32. PubMed ID: 30755254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycetoma in north-western Yemen: Clinico-epidemiological and histopathological study.
    Khatri ML; Al Kubati SAS; Gaffer IA; Majeed SMA
    Indian J Dermatol Venereol Leprol; 2022; 88(5):615-622. PubMed ID: 35389029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Madurella mycetomatis infection of the foot: a case report of a neglected tropical disease in a non-endemic region.
    Karrakchou B; Boubnane I; Senouci K; Hassam B
    BMC Dermatol; 2020 Jan; 20(1):1. PubMed ID: 31918687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects.
    Elkheir LYM; Haroun R; Mohamed MA; Fahal AH
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008307. PubMed ID: 32853199
    [No Abstract]   [Full Text] [Related]  

  • 6. Subcutaneous facial mycosis in a child due to Madurella mycetomatis.
    Mirza SH; Gardezi AH; Khan Y; Wiqar MA
    J Pak Med Assoc; 2007 Sep; 57(9):466-8. PubMed ID: 18072643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple extensive Madurella mycetomatis eumycetoma lesions: a case report and review of the literature.
    Zaid DM; Bakheet OE; Ahmed ES; Abdalati F; Mhmoud NA; Mohamed ESW; Bakhiet SM; Siddig EE; Fahal AH
    Trans R Soc Trop Med Hyg; 2021 Apr; 115(4):411-414. PubMed ID: 33406268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycetoma: a unique neglected tropical disease.
    Zijlstra EE; van de Sande WWJ; Welsh O; Mahgoub ES; Goodfellow M; Fahal AH
    Lancet Infect Dis; 2016 Jan; 16(1):100-112. PubMed ID: 26738840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal Activity of Natural Naphthoquinones and Anthraquinones against Madurella mycetomatis.
    Ma J; Todd M; van de Sande WWJ; Biersack B
    Chem Biodivers; 2023 May; 20(5):e202300151. PubMed ID: 37067830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.
    van de Sande WWJ; Fahal AH
    Clin Microbiol Rev; 2024 Jun; 37(2):e0003423. PubMed ID: 38690871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden.
    Ahmed AO; van Leeuwen W; Fahal A; van de Sande W; Verbrugh H; van Belkum A
    Lancet Infect Dis; 2004 Sep; 4(9):566-74. PubMed ID: 15336224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole.
    Nyuykonge B; Lim W; van Amelsvoort L; Bonifaz A; Fahal A; Badali H; Abastabar M; Verbon A; van de Sande W
    Mycoses; 2022 Jun; 65(6):650-655. PubMed ID: 35398930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycetoma in the Sudan: an update from the Mycetoma Research Centre, University of Khartoum, Sudan.
    Fahal A; Mahgoub el S; El Hassan AM; Abdel-Rahman ME
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003679. PubMed ID: 25816316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naphthylisoquinoline alkaloids: novel agents against the causative pathogens of eumycetoma and actinomycetoma-
    Khalid SA; Abd Algaffar S; Tajuddeen N; Lombe BK; Bringmann G
    Antimicrob Agents Chemother; 2024 May; 68(5):e0161223. PubMed ID: 38602413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella.
    Lim W; Konings M; Parel F; Eadie K; Strepis N; Fahal A; Verbon A; van de Sande WWJ
    Med Mycol; 2022 Feb; 60(2):. PubMed ID: 35064672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eumycetoma by Madurella grisea. Report of the first case observed in the southern Brazilian region.
    Severo LC; Vetoratto G; Oliveira Fde M; Londero AT
    Rev Inst Med Trop Sao Paulo; 1999; 41(2):139-42. PubMed ID: 10413963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eumycetoma and actinomycetoma--an update on causative agents, epidemiology, pathogenesis, diagnostics and therapy.
    Nenoff P; van de Sande WW; Fahal AH; Reinel D; Schöfer H
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1873-83. PubMed ID: 25726758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using (1,3)-β-D-glucan concentrations in serum to monitor the response of azole therapy in patients with eumycetoma caused by Madurella mycetomatis.
    Nyuykonge B; Siddig EE; Nyaoke BA; Zijlstra EE; Verbon A; Bakhiet SM; Fahal AH; van de Sande WWJ
    Mycoses; 2024 Jan; 67(1):e13664. PubMed ID: 37872649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plantar Eumycetoma by Madurella mycetomatis in a heart-transplanted patient living in Portugal.
    Cunha N; Martins ML; Fradinho N; Martins P; Cabete J
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):e182-e183. PubMed ID: 29150882
    [No Abstract]   [Full Text] [Related]  

  • 20. Paecilomyces lilacinus eumycetoma.
    Motswaledi HM; Mathekga K; Sein PP; Nemutavhanani DL
    Int J Dermatol; 2009 Aug; 48(8):858-61. PubMed ID: 19659864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.